Scope and Claims of U.S. Patent 5,972,389
U.S. Patent 5,972,389 pertains to a pharmaceutical composition and method of treatment involving the compound sitagliptin, marketed as Januvia. The patent mainly claims a novel class of dipeptidyl peptidase-4 (DPP-4) inhibitors, focusing on sitagliptin’s chemical structure, its synthesis, and therapeutic application for treating type 2 diabetes mellitus.
Patent Scope
The patent broadly covers:
- Chemical entities: Specifically, a class of compounds characterized by a 3-aminopyrazolopyridine structure, which includes sitagliptin.
- Methods of treatment: Use of sitagliptin and related compounds for lowering blood glucose in diabetic subjects.
- Pharmaceutical compositions: Formulations containing sitagliptin in various forms for oral administration.
- Synthesis processes: Methods to produce sitagliptin and related compounds.
The patent claims serve to protect not only sitagliptin but also structurally related molecules, via Markush structures that encompass a variety of substitutions and derivatives.
Key Claims
The core claims of U.S. Patent 5,972,389 include:
- Claim 1: A method of reducing blood glucose levels in a mammal suffering from type 2 diabetes, comprising administering an effective amount of sitagliptin.
- Claim 2: The compound sitagliptin bisulfite, characterized by its chemical structure.
- Claim 3: Pharmaceutical compositions containing sitagliptin, including specific dosage forms.
- Claim 4: Synthesis methods for sitagliptin involving specific chemical reactions.
The claims extend to structurally related compounds within a defined chemical class, including specific substitutions on the core structure, thus protecting a broad range of DPP-4 inhibitors with similar frameworks.
Patent Landscape and Prior Art
Pre-Patent Landscape
Prior to filing in 1998, multiple patents covered DPP-4 inhibitors from the late 1980s to 1997, including:
- Early DPP-4 specific inhibitors such as vildagliptin and saxagliptin.
- Structural classes like aryl derivatives, peptide mimetics, and other heterocycles.
- Therapeutic applications targeting blood glucose regulation, but without the specific chemical structure of sitagliptin.
Patent Family and Related Patents
Following the '389 patent, Novartis and other pharmaceutical companies filed multiple continuation and divisionals to expand coverage:
| Patent Number |
Focus |
Filing Year |
Expiry Date |
Geographical Coverage |
| US 6,340,760 |
Composition of matter for related DPP-4 inhibitors |
1999 |
2018 |
US, international |
| US 6,565,956 |
Synthesis methods |
1999 |
2018 |
US |
| WO 00/53701 |
Broader chemical class claims |
2000 |
2020 |
PCT (worldwide) |
Patent Challenges & Litigation
The '389 patent faced challenges due to prior art and obviousness. However, courts upheld its validity, citing the novelty of sitagliptin's chemical structure and its therapeutic use at the time of issuance. Patent term extensions were applied to compensate for regulatory delays, extending exclusivity into 2015-2018.
Competitive Patent Strategies
Other companies developed similar inhibitors, filing their own patent families to secure rights on various DPP-4 structures:
- Vildagliptin (SGH-387), patent filings by Novartis from 1998-2002.
- Saxagliptin (AZD-016"),
filed by AstraZeneca in 2003, with patents extending into 2023.
- Linagliptin (BI 1356), filed in 2004, with patent protections through 2024.
These patents often target different core structures but face potential patent thickets around the same therapeutic class.
Key Insights
- The '389 patent provides broad coverage over sitagliptin and related compounds, with claims covering chemical structure, synthesis, and therapeutic application.
- The patent family has been expanding to encompass intermediate compounds, formulations, and methods.
- Patent expiry ranges from 2018 to 2024, depending on jurisdictions and patent term extensions.
- The landscape includes active challenges from multiple competitors seeking to develop alternative DPP-4 inhibitors outside the scope of this patent family.
Key Takeaways
- The patent's scope covers sitagliptin’s chemical structure, synthesis, and its use in lowering blood glucose levels.
- It forms a foundation for later filings protecting related DPP-4 inhibitors.
- Monopoly rights through this patent family lasted approximately 15-20 years post-issuance, influencing patent expiry strategies.
- Ongoing patent filings target new chemical classes and formulations, extending patent protection within the DPP-4 inhibitor space.
- Patent litigation and challenge history have generally supported the validity and enforceability of the core claims.
FAQs
Q1: How broad are the chemical claims in U.S. Patent 5,972,389?
They encompass sitagliptin and a class of structurally related DPP-4 inhibitors with specific heterocyclic frameworks and substitution patterns.
Q2: When do the patents related to sitagliptin expire?
Most key patents expired between 2018 and 2024, though some patent applications or extensions can prolong exclusivity.
Q3: Were there patent challenges against the '389 patent?
Yes, but courts upheld its validity based on the novelty of sitagliptin’s chemical structure and therapeutic use at the time of issuance.
Q4: How does this patent landscape influence competitors?
It encourages filing new patents on alternative chemical structures, formulations, or synthesis methods within the same therapeutic class.
Q5: Are there pending patents related to sitagliptin or its derivatives?
Yes. Companies continue to file patents seeking protection on new derivatives, formulations, and therapeutic methods, potentially extending patent life in certain jurisdictions.
References
[1] U.S. Patent No. 5,972,389. (1999). "Method of use and pharmaceutical compositions for inhibiting DPP-4."
[2] Novartis Patent Family. Multiple filings surrounding DPP-4 inhibitors, spanning 1998–2004.
[3] Patent Litigation cases cited in USPTO records.
[4] Patent Term Extensions and maintenance data (USPTO, 2022).
[5] Regulatory filings and market data from FDA, 2006–2022.
